Trial record 1 of 1 for:    NCT00843726
Previous Study | Return to List | Next Study

Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer

This study is currently recruiting participants.
Verified March 2014 by Roswell Park Cancer Institute
Sponsor:
Information provided by (Responsible Party):
Roswell Park Cancer Institute
ClinicalTrials.gov Identifier:
NCT00843726
First received: February 12, 2009
Last updated: March 25, 2014
Last verified: March 2014

February 12, 2009
March 25, 2014
September 2008
April 2020   (final data collection date for primary outcome measure)
  • Incidence of RTOG grade 3 or higher toxicity [ Time Frame: 1year ] [ Designated as safety issue: Yes ]
  • Overall survival [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Correlation between blood and serum markers and survival and toxicity [ Time Frame: 4 years ] [ Designated as safety issue: No ]
  • Incidence of RTOG grade 3 or higher toxicity [ Designated as safety issue: Yes ]
  • Overall survival [ Designated as safety issue: No ]
  • Correlation between blood and serum markers and survival and toxicity [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00843726 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer
A Phase II Randomized Study of 2 Stereotactic Body Radiation Therapy (SBRT) Regimens for Medically Inoperable Patients With Node Negative, Peripheral Non-Small Cell Lung Cancer

RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. It is not yet known which regimen of radiation therapy is more effective in treating patients with non-small cell lung cancer.

PURPOSE: This randomized phase II trial is studying the side effects of two radiation therapy regimens and to see how well they work in treating patients with stage I or stage II non-small cell lung cancer.

OBJECTIVES:

Primary

  • To compare the incidence of toxicity with two established stereotactic body radiotherapy (SBRT) regimens in patients with node-negative, peripheral stage I or II non-small cell lung cancer.

Secondary

  • To compare quality of life, patterns of failure, disease-free survival, and overall survival of these patients after treatment with one of two established SBRT regimens.
  • To correlate outcomes and toxicities with imaging and patient and tumor biomarkers.

OUTLINE: Patients are stratified according to Karnofsky performance status and treatment center. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients undergo 1 high-dose fraction of stereotactic body radiotherapy (SBRT).
  • Arm II: Patients undergo 3 high-dose fractions (approximately 1 week apart) of SBRT.

Quality of life is assessed periodically by the EORTC QLQ-C30 and -LC13 questionnaires

Blood and tissue samples may be collected periodically and examined for biomarkers via ELISA and immunoblotting.

After completion of study treatment, patients are followed for 5 years.

Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Lung Cancer
Radiation: stereotactic body radiation therapy
Patients undergo 1 or 3 high-dose fractions
  • Experimental: Arm I
    Patients undergo 1 high-dose fraction of stereotactic body radiotherapy (SBRT).
    Intervention: Radiation: stereotactic body radiation therapy
  • Experimental: Arm II
    Patients undergo 3 high-dose fractions (approximately 1 week apart) of SBRT.
    Intervention: Radiation: stereotactic body radiation therapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
98
Not Provided
April 2020   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Histologically confirmed non-small cell lung cancer

    • Node-negative disease
    • Peripheral disease
  • T1-T3, N0 disease measuring ≤ 5 cm

    • No T2-T3 tumors > 5 cm or T3 tumor based on chest wall involvement
  • Surgically resectable primary disease, but patient refuses surgery or is deemed to be medically inoperable
  • No metastatic disease
  • No tumor within the zone of the proximal bronchial tree, defined as a volume of 2 cm in all directions

PATIENT CHARACTERISTICS:

  • Not pregnant
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No other conditions deemed by the PI or associates to make the patient ineligible for protocol investigations, procedures, and high-dose external beam radiotherapy (e.g., unable to lie still and breathe reproducibly)

PRIOR CONCURRENT THERAPY:

  • No prior thoracic radiotherapy
Both
18 Years and older
No
Not Provided
United States
 
NCT00843726
I 124407, I 124407
Yes
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Not Provided
Principal Investigator: Anurag K. Singh, MD Roswell Park Cancer Institute
Roswell Park Cancer Institute
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP